Chiesi Farmaceutici S.p.a.
Clinical trials sponsored by Chiesi Farmaceutici S.p.a., explained in plain language.
-
New hope for lung scarring: experimental drug zampilimab enters Mid-Stage trial
Disease control Not yet recruitingThis study tests an experimental drug called zampilimab in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. Participants will receive one of two doses of the drug or a placebo for 24 weeks, with an optional 24-week…
Phase: PHASE2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New pill aims to cut dangerous lung attacks in bronchiectasis patients
Disease control Not yet recruitingThis study tests a daily tablet called Florensocatib (CHF10196) to see if it can reduce the number of serious lung flare-ups in people with bronchiectasis, a long-term lung condition. About 1800 participants aged 12 to 85 will take either the drug or a placebo for up to 78 weeks,…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New triple inhaler aims to tame uncontrolled asthma
Disease control Not yet recruitingThis study tests a new inhaler (CHF 5993) that combines three medicines—an anti-inflammatory, a long-acting bronchodilator, and another bronchodilator—against a standard two-medicine inhaler in Chinese adults whose asthma is not well controlled despite current treatment. About 55…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC